Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial
Rasmussen B, Altermatt H, Gelber R, Castiglione-Gertsch M, Goldhirsch A, Gusterson B, Thürlimann B, Coates A, Viale G, Braye S, Lacroix-Triki M, Regan M, Lykkesfeldt A, Dell'Orto P, Del Curto B, Henriksen K, Mastropasqua M, Price K, Méry E, BIG 1-98 Collaborative and International Breast Cancer Study Groups. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. The Lancet 2008; 9:23-8.
Jan 1, 2008
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial
Jan 1, 2008
The Lancet 2008; 9:23-8
Rasmussen Birgitte B, Altermatt Hans J, Gelber Richard D, Castiglione-Gertsch Monica, Goldhirsch Aron, Gusterson Barry A, Thürlimann Beat, Coates Alan S, Viale Giuseppe, Braye Stephen, Lacroix-Triki Magali, Regan Meredith M, Lykkesfeldt Anne E, Dell'Orto Patrizia, Del Curto Barbara, Henriksen Katrine L, Mastropasqua Mauro G, Price Karen N, Méry Eliane, BIG 1-98 Collaborative and International Breast Cancer Study Groups
more
